



A Member of the Roche Group

October 1, 2013

Submission Request
c/o Joan McClure
National Comprehensive Cancer Network (NCCN)
275 Commerce Dr, Suite 300
Fort Washington, PA 19034

Dear Ms. McClure:

Enclosed is a copy of the recently revised prescribing information for Perjeta[®] (pertuzumab) for your review and product information updating needs. On September 30, 2013, the FDA granted accelerated approval of a Perjeta regimen for neoadjuvant treatment (use before surgery) in patients with high-risk, HER2-positive early stage breast cancer.

I hope this information is helpful to you in updating your drug information publications. If you have any questions or need additional assistance, please contact me directly at (650) 467-9538 or by email at toy.karyn@gene.com.

Sincerely,

A handwritten signature in black ink, appearing to read 'Karyn Toy', is written over a light blue horizontal line.

Karyn Toy, PharmD, Scientist
Medical Communications, Medical Affairs
Genentech, Inc.
1 DNA Way, South San Francisco, CA 94080
Phone (800) 821-8590 | Email mc-mc-d@gene.com

Enclosure:
Perjeta Prescribing Information